X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ACTAVIS (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ACTAVIS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ACTAVIS
Dec-18
NOVARTIS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs75813,413-   
Low Rs5798,998-   
Sales per share (Unadj.) Rs228.43,290.3-  
Earnings per share (Unadj.) Rs31.7-1,059.8-  
Cash flow per share (Unadj.) Rs32.8346.7-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.113,571.0-  
Shares outstanding (eoy) m24.69332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.4 85.9%   
Avg P/E ratio x21.1-10.6 -199.2%  
P/CF ratio (eoy) x20.432.3 63.1%  
Price / Book Value ratio x2.20.8 272.5%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5053,726,975 0.4%   
No. of employees `0000.716.9 4.0%   
Total wages/salary Rs m1,4450-   
Avg. sales/employee Rs Th8,441.364,754.7 13.0%   
Avg. wages/employee Rs Th2,163.60-   
Avg. net profit/employee Rs Th1,173.1-20,857.5 -5.6%   
INCOME DATA
Net Sales Rs m5,6391,094,355 0.5%  
Other income Rs m1,71820,928 8.2%   
Total revenues Rs m7,3571,115,283 0.7%   
Gross profit Rs m-6328,678 -0.2%  
Depreciation Rs m25467,813 0.0%   
Interest Rs m5563,151 0.1%   
Profit before tax Rs m1,575-481,358 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0122,766 0.0%   
Tax Rs m792-6,100 -13.0%   
Profit after tax Rs m784-352,492 -0.2%  
Gross profit margin %-1.12.6 -42.3%  
Effective tax rate %50.31.3 3,965.5%   
Net profit margin %13.9-32.2 -43.1%  
BALANCE SHEET DATA
Current assets Rs m9,522448,847 2.1%   
Current liabilities Rs m3,296397,065 0.8%   
Net working cap to sales %110.44.7 2,333.3%  
Current ratio x2.91.1 255.6%  
Inventory Days Days3720 187.0%  
Debtors Days Days2866 42.9%  
Net fixed assets Rs m46123,875 0.0%   
Share capital Rs m1230-   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,3364,513,702 0.2%   
Long term debt Rs m01,589,438 0.0%   
Total assets Rs m11,1057,055,944 0.2%  
Interest coverage x29.5-6.6 -445.2%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.2 327.4%   
Return on assets %7.6-4.1 -184.2%  
Return on equity %10.7-7.8 -136.8%  
Return on capital %22.2-4.8 -459.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,610390,972 0.4%  
From Investments Rs m687214,788 0.3%  
From Financial Activity Rs m-2,677-671,025 0.4%  
Net Cashflow Rs m-380-64,939 0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.32 Rs / USD

Compare NOVARTIS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: ALEMBIC LTD  TTK HEALTHCARE  STRIDES PHARMA SCIENCE  WYETH LTD  CADILA HEALTHCARE  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 25, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - AJANTA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS